Enhanced antitumor effects by preventing renal damage due to the adverse effects of an anticancer agent - Usefulness of a megalin antagonist

March 04, 2021

A research team of Masashi Arita (graduate student), Assistant Professor Nobumasa Aoki (emergency medicine), and Lecturer Satoshi Watanabe of the Department of Respiratory Medicine and Infectious Diseases and Professor Akihiko Saito of the Department of Applied Molecular Medicine, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences revealed the mechanism of renal damage caused by anticancer agent cisplatin and enhanced the antitumor effects of cisplatin by preventing renal damage. The results of the study may increase the therapeutic effects of cisplatin at an increased dose and ensure the safety of cisplatin even in those with renal impairment.

Key results of the research

- Although cisplatin is effective for various cancers, its dose is limited by renal damage due to adverse effects.
- Renal damage could be prevented by suppressing the action of megalin involved in the renal damage.
- Renal damage caused by cisplatin was alleviated, which increased the antitumor effects.

Publication Details

Title: Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity
Journal: Scientific Reports
Authors: Masashi Arita, Satoshi Watanabe, Nobumasa Aoki, Shoji Kuwahara, Ryo Suzuki, Sawako Goto, Yuko Abe, Miho Takahashi, Miyuki Sato, Satoshi Hokari, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Masachika Hayashi, Yasuyoshi Ohshima, Hideyuki Kabasawa, Michihiro Hosojima, Toshiyuki Koya, Akihiko Saito, Toshiaki Kikuchi
DOI: 10.1038/s41598-020-80853-6

More News

All News